Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $1.18M invested in Atossa Therapeutics in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 10 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
71% more capital invested
Capital invested by funds: $688K → $1.18M (+$488K)
1.24% more ownership
Funds ownership: 0.03% → 1.27% (+1.2%)
26% less funds holding
Funds holding: 19 → 14 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.22M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$390K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$21.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.39K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$80K |
| 2 |
Barclays
London,
United Kingdom
|
-$72K |
| 3 |
VF
Virtu Financial
New York
|
-$39K |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$26K |
| 5 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$16K |
ATOS Hedge Fund Activity: Q2 2018 in Review
14 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2018, worth a combined $1.18M — up 71% from $688K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATOS and 5 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.22M. The largest seller was Citadel Advisors, exiting entirely with an estimated $80K sold.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2018, down from 19 in Q1 2018.
- Funds reported $1.18M of Atossa Therapeutics stock for Q2 2018, up 71% quarter-over-quarter.
- 5 funds opened new Atossa Therapeutics positions in Q2 2018 and 10 closed out, a net change of -5 holders.
- The largest Atossa Therapeutics buyer in Q2 2018 was Sabby Management, an estimated $1.22M added.
- The largest Atossa Therapeutics seller in Q2 2018 was Citadel Advisors, an estimated $80K sold.
Based on aggregated 13F filings for Q2 2018.